Outcomes of refractory or relapsed Hodgkin lymphoma patients with post-autologous stem cell transplantation brentuximab vedotin maintenance: a French multicenter observational cohort study

被引：11

作者：

Marouf, Amira ^{[1
,2
,3
]}

Cottereau, Anne Segolene ^{[2
,4
]}

Kanoun, Salim ^{[5
]}

Deschamps, Paul ^{[1
,2
]}

Meignan, Michel ^{[6
,7
]}

Franchi, Patricia ^{[1
,2
]}

Sibon, David ^{[8
,9
]}

Antoine, Clara ^{[6
]}

Gastinne, Thomas ^{[10
]}

Borel, Cecile ^{[11
]}

Hammoud, Mohammad ^{[12
]}

Sicard, Guillaume ^{[13
]}

Gille, Romane ^{[14
]}

Cavalieri, Doriane ^{[15
]}

Stamatoullas, Aspasia ^{[16
]}

Filliatre-Clement, Lauriane ^{[16
]}

Lazarovici, Julien ^{[17
]}

Chauchet, Adrien ^{[18
]}

Fornecker, Luc-Matthieu ^{[19
,20
,21
]}

Amorin, Sandy ^{[22
]}

Rocquet, Mathieu ^{[1
]}

Raus, Nicole ^{[23
,24
]}

Burroni, Barbara ^{[25
,26
]}

Rubio, Marie Therese ^{[24
,27
,28
]}

Bouscary, Didier ^{[1
,2
,29
]}

Quittet, Philippe ^{[30
]}

Casasnovas, Rene Olivier ^{[31
,32
]}

Brice, Pauline ^{[33
]}

Ghesquieres, Herve ^{[34
]}

Tamburini, Jerome ^{[1
,2
,29
,35
]}

Deau, Benedicte ^{[1
,2
]}

机构：

[1] Hop Cochin, AP HP, Dept Hematol, Paris, France

[2] Univ Paris, Paris, France

[3] INSERM, UMR 1163, Inst Imagine, Paris, France

[4] Hop Cochin, AP HP, Dept Nucl Med, Paris, France

[5] INSERM, Canc Res Ctr Toulouse CRCT, Team 9, UMR 1037, Toulouse, France

[6] Hop Henri Mondor, Lymphoma Study Assoc Imaging, Lymphoma Acad Res Org LYSARC, Creteil, France

[7] Paris Est Univ, Creteil, France

[8] Necker Univ Hosp, Hematol Dept, AP HP, Paris, France

[9] Necker Univ Hosp, Inst Necker Enfants Malades, AP HP, INSERM U1151, Paris, France

[10] Nantes Univ Hosp, Dept Hematol, Nantes, France

[11] Inst Univ Canc Toulouse Oncopole, Dept Hematol, Toulouse, France

[12] Hop Henri Mondor, Lymphoid Malignancies Unit, Creteil, France

[13] Aix Marseille Univ, Dept Hematol, Marseille, France

[14] Ctr Leon Berard, Dept Med Oncol, Lyon, France

[15] Ctr Hosp Univ CHU Estaing, Dept Hematol, Clermont Ferrand, France

[16] Clin Louis Pasteur, Dept Hematol, Nancy, France

[17] Inst Gustave Roussy, Dept Hematol, Villejuif, France

[18] CHU Besancon, Dept Hematol, Besancon, France

[19] Strasbourg Univ Hosp, Strasbourg, France

[20] INSERM S 1113, Strasbourg, France

[21] Strasbourg Univ, Fac Med, Strasbourg, France

[22] Hop St Vincent de Paul, Dept Hematol, Lille, France

[23] Hop Lyon Sud, Dept Hematol, Pierre Benite, France

[24] Soc Francophone Greffe Moelle & Therapie Cellulai, Pierre Benite, France

[25] Hop Cochin, AP HP, Serv Pathol, Paris, France

[26] Paris Univ, Sorbonne Univ, INSERM, Ctr Rech Cordeliers, Paris, France

[27] Hop Brabois, CHRU Nancy, Dept Hematol, Nancy, France

[28] Biopole Univ Lorraine, CNRS UMR 7365, Equipe 6, Vandoeuvre Les Nancy, France

[29] INSERM, Inst Cochin, U1016, Paris, France

[30] Univ Montpellier, Dept Hematol, Montpellier, France

[31] Dijon Univ Hosp, Dept Hematol, Dijon, France

[32] CHU Dijon, INSERM UMR 1231, Dijon, France

[33] Hop St Louis, CHU Paris GH St Louis Lariboisiere F Widal, Dept Hematol, Paris, France

[34] Ctr Hosp Lyon Sud, Dept Hematol, Pierre Benite, France

[35] Univ Geneva, Fac Med, Translat Res Ctr Oncohematol, Geneva 4, Switzerland

来源：

HAEMATOLOGICA | 2022年 / 107卷 / 07期

关键词：

THERAPY; COMBINATION; 2ND-LINE;

D O I：

10.3324/haematol.2021.279564

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页码：1681 / 1686

页数：6

共 50 条

[21] Brentuximab vedotin containing salvage followed by consolidation post autologous hematopoietic stem cell transplantation in high risk relapsed refractory classical Hodgkin lymphoma
Moussab Damlaj
Khadega A. Abuelgasim
Ayman Alhejazi
Bader Alahmari
Ahmed Alaskar
Mohsen Alzahrani
Bone Marrow Transplantation, 2020, 55 : 2322 - 2325
[22] A CASE OF REFRACTORY HODGKIN LYMPHOMA TREATED WITH BRENTUXIMAB VEDOTIN MAINTENANCE THERAPY AFTER AUTOLOGOUS PERIPHERAL BLOOD STEM CELL TRANSPLANTATION
Kondo, Hiroaki
Osone, Shinya
Aoi, Teruki
Nishimoto, Sota
Yoshida, Hideki
Imamura, Toshihiko
Iehara, Tomoko
PEDIATRIC BLOOD & CANCER, 2022, 69
[23] Safety and efficacy of four cycles of Brentuximab Vedotin as consolidation after autologous peripheral stem cell transplantation in relapsed/refractory Hodgkin lymphoma
Kort, Jeries
Chidiac, Amanda
El Sayed, Rola
Massoud, Radwan
Nehme, Rita
Bazarbachi, Ali
El-Cheikh, Jean
LEUKEMIA & LYMPHOMA, 2020, 61 (07) : 1732 - 1735
[24] BRENTUXIMAB VEDOTIN IN PATIENTS WHO ARE INELIGIBLE FOR AUTOLOGOUS STEM CELL TRANSPLANT WITH RELAPSED OR REFRACTORY HODGKIN LYMPHOMA: A UNITED KINGDOM AND GERMANY RETROSPECTIVE STUDY
Broeckelmann, P. J.
Zagadailov, E. A.
Corman, S.
Hagan, M.
Chirikov, V.
Johnson, C.
Macahilig, C.
Seal, B.
Dalal, M. R.
Illidge, T.
HAEMATOLOGICA, 2016, 101 : 50 - 51
[25] Brentuximab vedotin in patients with relapsed or refractory Hodgkin lymphoma who are Ineligible for autologous stem cell transplant: A Germany and United Kingdom retrospective study
Broeckelmann, Paul J.
Zagadailov, Erin A.
Corman, Shelby L.
Chirikov, Viktor
Johnson, Courtney
Macahilig, Cynthia
Seal, Brian
Dalal, Mehul R.
Illidge, Tim
EUROPEAN JOURNAL OF HAEMATOLOGY, 2017, 99 (06) : 553 - 558
[26] Brentuximab vedotin consolidation post-autologous stem cell transplant in Hodgkin lymphoma patients at risk of residual disease: number needed to treat
Gautam, Ashish
Zhu, Yanyan
Ma, Esprit
Lee, Shih-Yuan
Zagadailov, Erin
Teasell, Jeremy
Richhariya, Akshara
Bonthapally, Vijayveer
Huebner, Dirk
LEUKEMIA & LYMPHOMA, 2018, 59 (01) : 69 - 76
[27] Autologous stem cell transplantation in refractory or relapsed Hodgkin lymphoma
Afonso, S.
Carvalhais, I.
Carneiro, A.
Araujo, J.
Principe, F.
Guimaraes, J. E.
BONE MARROW TRANSPLANTATION, 2017, 52 : S440 - S441
[28] Efficacy of Brentuximab Vedotin Maintenance Therapy Following Autologous Stem Cell Transplantation in Patients with Relapsed/Refractory Classical Hodgkin Lymphoma with and without Pre-Transplant Exposure to Novel Agents
Falade, Ayo S.
Redd, Robert A.
Shah, Harsh
Baron, Kelsey
Iyengar, Siddharth
Desai, Sanjal H.
Ansell, Stephen M.
Micallef, Ivana
Nedved, Adrienne
Ganesan, Nivetha
Chang, Tiffany
Shah, Gunjan L.
Stuver, Robert
Moskowitz, Alison
Mei, Matthew Genyeh
Othman, Tamer
Ong, Shin Yeu
Herrera, Alex F.
Armand, Philippe
Merryman, Reid W.
BLOOD, 2023, 142
[29] Brentuximab Vedotin As Consolidation Therapy Post Hematopoietic Stem Cell Transplantation for Patients with Relapsed or Refractory Hodgkin Lymphoma: A Real World Analysis of the Colombian Experience
Patino, Bonell
Acon-Solano, Cristina
Pereira, Mario
Enciso-Olivera, Leonardo
Otero-de la Hoz, Diana
Cordero, Humberto Martinez
Spirko, Paola
Solano-Vega, Julio
Arevalo-Zambrano, Monica
Heider, Ulrike
Ruiz-Patino, Alejandro
Sossa, Claudia Lucia
Pena, Angela Maria
Chalela, Claudia Marcela
Karduss, Amado
Leon-Basantes, Guillermo
Abello, Virginia
Espinosa, Daniel Lorenzo
Guerrero, Paola
Guerrero, Alvaro
Herrera, Juan Manuel
Osuna, Monica
Perdomo, Ivan
Rosales, Carmen
Omana, Paola
Villarroya, Natalia
Rodriguez-Sanjuan, Victor
Sandoval-Sus, Jose
BLOOD, 2019, 134
[30] Effect of cumulative dose of brentuximab vedotin maintenance in relapsed/refractory classical Hodgkin lymphoma after autologous stem cell transplant: an analysis of real-world outcomes
Wagner, Charlotte B.
Boucher, Ken
Nedved, Adrienne
Micallef, Ivana N.
Desai, Sanjal
Hatic, Haris
Goyal, Gaurav
Zacholski, Erin
Fegley, Amanda
Sigmund, Audrey M.
Bond, David A.
Samuels, Courtney
Kamdar, Manali K.
Aqeel, Sheeba Ba
Torka, Pallawi
Macdougall, Kira
Borogovac, Azra
Rajeeve, Sridevi
Sundaram, Suchitra
Fedak, Kalub
Modi, Dipenkumar
Travers, Elizabeth
Ayyappan, Sabarish
Chilakamarri, Nitin
Brem, Elizabeth A.
Ermann, Daniel A.
Fitzgerald, Lindsey A.
Hu, Boyu
Stephens, Deborah M.
Shah, Harsh
HAEMATOLOGICA, 2023, 108 (11) : 3025 - 3032

← 1 2 3 4 5 →